Oxford Biomedical Research
P.O. Box 522
About Oxford Biomedical ResearchOxford Biomedical Research, incorporated in 1984 by Denis M. Callewaert Ph.D., a professor of Chemistry, and the Director of the Center for Biomedical Research at Oakland University in Michigan.
Company operations, conducted at its 4,000 square foot facility, are located in an industrial park in Rochester Hills, MI. The Company develops and markets over 400 products for the biomedical and pharmaceutical research community, and performs research and development under the auspices of grants and contracts from the National Institute of Health.
OBR has developed a large number of collaborations with internationally recognized scientists in the field of molecular oxygenation reactions. Most of these scientists hold senior positions in the Vanderbilt University School of Medicine. The Company has licensed several key technologies and is further developing clinical diagnostic tests in collaboration with the Vanderbilt faculty and other major academic and government research installations.
Last Updated: 07-30-02
5 articles with Oxford Biomedical Research
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
Oxford Biomedica plc, a leading gene and cell therapy group, and Homology Medicines, Inc., a genetic medicines company, announced that the companies have agreed to establish a high-performing, full scope Adeno-Associated Virus Manufacturing and Innovation Business in the U.S.
Oxford BioMedica notes the longer-term analyses from pivotal Kymriah® trials, which showed durable responses are maintained in patients with advanced blood cancers
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA and JULIET pivotal trials in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL), respectively.
Oxford Biomedical Research Signs Contract With GENALICE For Its Breakthrough Sequenced DNA Data Processing Solution
Oxford Biomedical Research Awarded National Institutes of Health (NIH) Contract to Develop Assay for Anti-inflammatory & Anticancer Efficacy Biomarker